Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTLCVE:GPHNYSEMKT:IGCNYSE:OGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$0.88+2.8%$1.11$0.86▼$1.60$2.90M1.0636,512 shs3,945 shsGPHGraphite OneC$0.90-4.3%C$0.94C$0.55▼C$1.07C$91.13M1.0257,929 shs39,352 shsIGCIGC Pharma$0.29-11.4%$0.31$0.26▼$0.91$22.71M1.21479,179 shs214,616 shsOGNOrganon & Co.$14.71+4.1%$15.28$13.87▼$23.10$3.79B0.762.55 million shs2.34 million shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences-1.70%-11.43%-19.62%-18.86%-43.58%GPHGraphite One+1.08%-1.05%-4.08%+38.24%+11.90%IGCIGC Pharma-0.70%-7.47%-1.04%-15.18%+28,499,900.00%OGNOrganon & Co.-5.41%-4.24%-5.30%-5.40%-23.70%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTLArtelo Biosciences2.4369 of 5 stars3.83.00.00.01.60.01.3GPHGraphite OneN/AN/AN/AN/AN/AN/AN/AN/AIGCIGC Pharma1.8258 of 5 stars3.50.00.00.02.31.70.0OGNOrganon & Co.4.8042 of 5 stars3.21.03.33.73.51.73.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTLArtelo Biosciences 3.50Strong Buy$5.50521.82% UpsideGPHGraphite One 0.00N/AN/AN/AIGCIGC Pharma 3.00Buy$3.881,240.83% UpsideOGNOrganon & Co. 2.43Hold$20.8041.40% UpsideCurrent Analyst Ratings BreakdownLatest ARTL, OGN, GPH, and IGC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/6/2025IGCIGC PharmaAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.50 ➝ $3.503/4/2025ARTLArtelo BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.002/27/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.002/24/2025IGCIGC PharmaAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $4.252/14/2025OGNOrganon & Co.BarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$26.00 ➝ $24.002/14/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $16.001/15/2025OGNOrganon & Co.TD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold1/14/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTLArtelo BiosciencesN/AN/AN/AN/A$4.12 per shareN/AGPHGraphite OneN/AN/AC$0.01 per share94.17C$0.44 per shareN/AIGCIGC Pharma$1.24M18.63N/AN/A$0.08 per share3.61OGNOrganon & Co.$6.40B0.59$4.71 per share3.12($0.27) per share-54.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTLArtelo Biosciences-$9.29M-$3.05N/AN/AN/AN/A-104.59%-94.06%5/12/2025 (Estimated)GPHGraphite One-C$4.90M-C$0.07N/A∞N/AN/A-10.96%-6.61%N/AIGCIGC Pharma-$13M-$0.11N/AN/AN/A-714.16%-122.44%-88.40%N/AOGNOrganon & Co.$864M$3.334.423.930.9013.49%431.62%8.03%5/1/2025 (Estimated)Latest ARTL, OGN, GPH, and IGC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/3/2025Q4 2024ARTLArtelo Biosciences-$0.74-$1.17-$0.43-$1.17N/AN/A2/13/2025Q4 2024OGNOrganon & Co.$0.92$0.83-$0.09$0.42$1.57 billion$1.59 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTLArtelo BiosciencesN/AN/AN/AN/AN/AGPHGraphite OneN/AN/AN/AN/AN/AIGCIGC PharmaN/AN/AN/AN/AN/AOGNOrganon & Co.$1.127.61%+25.99%33.63%N/ALatest ARTL, OGN, GPH, and IGC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/13/2025OGNOrganon & Co.quarterly$0.287.3%2/24/20252/24/20253/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTLArtelo BiosciencesN/A7.157.15GPHGraphite One0.021.090.33IGCIGC Pharma0.021.150.98OGNOrganon & Co.17.731.701.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTLArtelo Biosciences0.87%GPHGraphite One0.07%IGCIGC Pharma3.87%OGNOrganon & Co.77.43%Insider OwnershipCompanyInsider OwnershipARTLArtelo Biosciences0.83%GPHGraphite One28.81%IGCIGC Pharma31.48%OGNOrganon & Co.1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTLArtelo Biosciences53.28 million3.20 millionNot OptionableGPHGraphite One20101.25 millionN/ANot OptionableIGCIGC Pharma6179.69 million54.60 millionN/AOGNOrganon & Co.10,000257.95 million253.93 millionNot OptionableARTL, OGN, GPH, and IGC HeadlinesRecent News About These CompaniesWhy Organon (OGN) Could Beat Earnings Estimates AgainApril 2 at 1:15 PM | zacks.comOrganon acquires rights for Tofidence from BiogenApril 2 at 10:29 AM | markets.businessinsider.comNew Age Alpha Advisors LLC Takes Position in Organon & Co. (NYSE:OGN)April 2 at 4:23 AM | marketbeat.comKLP Kapitalforvaltning AS Purchases Shares of 54,400 Organon & Co. (NYSE:OGN)April 2 at 3:49 AM | marketbeat.comHere is What to Know Beyond Why Organon & Co. (OGN) is a Trending StockApril 1 at 10:00 AM | zacks.comOrganon Acquires TOFIDENCEâ„¢ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.April 1 at 8:00 AM | businesswire.comBrandywine Global Investment Management LLC Raises Stock Position in Organon & Co. (NYSE:OGN)April 1 at 5:34 AM | marketbeat.comElo Mutual Pension Insurance Co Takes Position in Organon & Co. (NYSE:OGN)April 1 at 4:13 AM | marketbeat.comMitsubishi UFJ Trust & Banking Corp Increases Holdings in Organon & Co. (NYSE:OGN)March 31 at 4:11 AM | marketbeat.comOrganon & Co. (NYSE:OGN) Shares Sold by Prudential Financial Inc.March 31 at 4:03 AM | marketbeat.comSei Investments Co. Sells 43,155 Shares of Organon & Co. (NYSE:OGN)March 31 at 3:37 AM | marketbeat.comOrganon, Shanghai Henlius Biotech: EMA validates MAA for HLX11March 28, 2025 | markets.businessinsider.comEasterly Investment Partners LLC Makes New Investment in Organon & Co. (NYSE:OGN)March 28, 2025 | marketbeat.comEuropean Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11March 28, 2025 | businesswire.comNatixis Advisors LLC Decreases Position in Organon & Co. (NYSE:OGN)March 28, 2025 | marketbeat.comOrganon (OGN) Falls More Steeply Than Broader Market: What Investors Need to KnowMarch 27, 2025 | zacks.comEntryPoint Capital LLC Purchases Shares of 27,939 Organon & Co. (NYSE:OGN)March 27, 2025 | marketbeat.comOrganon & Co. (NYSE:OGN) Shares Sold by Corient Private Wealth LLCMarch 27, 2025 | marketbeat.comRaymond James Financial Inc. Invests $4.19 Million in Organon & Co. (NYSE:OGN)March 27, 2025 | marketbeat.comProficio Capital Partners LLC Takes Position in Organon & Co. (NYSE:OGN)March 26, 2025 | marketbeat.comSound Shore Management Inc. CT Has $74.13 Million Holdings in Organon & Co. (NYSE:OGN)March 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARTL, OGN, GPH, and IGC Company DescriptionsArtelo Biosciences NASDAQ:ARTL$0.88 +0.02 (+2.84%) As of 03:28 PM EasternArtelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Graphite One CVE:GPHC$0.90 -0.04 (-4.26%) As of 02:56 PM EasternGraphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.IGC Pharma NYSEMKT:IGC$0.29 -0.04 (-11.38%) As of 12:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Organon & Co. NYSE:OGN$14.71 +0.58 (+4.10%) As of 03:34 PM EasternOrganon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Boeing Stock Upgraded After Beating Lockheed for Jet Deal Amazon Falls Back to a Key Support Line: Here's How to Play It Why Howmet Could Be the Sleeper Aerospace Name of 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
